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We assessed the influence of human leukocyte antigen (HLA)
alleles HLA-Bw4 and HLA-Bw6 on CD4 T cell recovery after
starting successful combination antiretroviral therapy in 265
individuals. The median gains in the CD4 T cell count after
4 years were 258 cells/mL for HLA-Bw4 homozygotes, 321
cells/mL for HLA-Bw4/Bw6 heterozygotes, and 363 cells/mL
for HLA-Bw6 homozygotes ( , compared with HLA-Pp .01
Bw4 homozygotes). HLA-Bw4 homozygosity appears to pre-
dict an impaired CD4 T cell recovery after initiation of com-
bination antiretroviral therapy.
Human leukocyte antigen (HLA) allelic variation influences the
course of HIV infection by shaping adaptive and innate im-
mune responses [1]. HLA genetic variation is most intense in
regions involved in antigen-derived peptide binding. However,
HLA-B molecules can also be categorized into 2 mutually ex-
clusive HLA-Bw4 and HLA-Bw6 variants defined by amino acid
sequence variation at residues 77–83 of the HLA a-1 domain
[2]. The HLA-Bw4 variant, defined primarily by the presence
at residue 80 of either isoleucine (“80I”) or threonine (“80T”),
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ligates to killer cell Ig-like receptors (KIR) expressed on natural
killer cells and selected T cell subsets, whereas the HLA-Bw6
variant (“80N”) has no known ligands.
HLA-Bw4 homozygosity is associated with control of the HIV
load, protection from AIDS [3], and decreased risk of HIV
transmission [4]. The interaction between HLA-Bw4 80I and
KIR3DS1 confers protection against progression to AIDS and
opportunistic infections [5, 6]. The influence of HLA-Bw4 and
HLA-Bw6 alleles on recovery of the CD4 T cell count after
commencement of combination antiretroviral therapy (cART)
is unknown. The aim of this study was to investigate the impact
of HLA-Bw4 and HLA-Bw6 alleles on CD4 T cell recovery after
commencement of successful cART, with incorporation of
known or potential predictors of response to cART as
covariates.
Methods. Our study included antiretroviral-naive, HIV-
infected individuals from the Swiss HIV Cohort Study and the
Western Australian HIV Cohort Study (SHCS and WAHIV,
respectively). All participants provided informed consent, in-
cluding consent for genetic testing. The primary analysis was
restricted to white men who had received successful, uninter-
rupted cART, to eliminate the potentially confounding effects
of ethnicity, sex, and treatment interruptions. Thereafter, the
influence of HLA-Bw4 and HLA-Bw6 alleles on CD4 T cell
recovery was also assessed in an expanded population that in-
cluded women and nonwhite participants. Successful cART was
defined as treatment that yielded an HIV RNA level !400 cop-
ies/mL (i.e., the lower limit of assay detection during most of
the study period) within 6 months and with which a suppressed
HIV load was maintained throughout the study. Follow-up was
censored at the point of the first virologic failure (HIV RNA
level, 400 copies/mL) or if cART was stopped for 11 month.
Sequenced-based, high-resolution HLA typing was performed
for all individuals, and HLA-Bw4 and HLA-Bw6 carriage was
determined on the basis of sequence variation at residues
77–83.
Increases in the CD4 T cell count after commencement of
cART were estimated by flexible piece-wise linear profiles using
mixed-effects regression, with use of S-Plus software, version
7.0 (Insightful Corp). In these analyses, the individual-specific
and population-average time trends in increases in the CD4 T
cell count are modeled (on the square-root scale) by contin-
uous, piece-wise linear functions, with change points at every
12 months. CD4 T cell counts at the time of cART initiation
(i.e., the baseline CD4 T cell count) influence increases in the
CD4 T cell count after commencement of cART [7]; therefore,
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Figure 1. Estimated median increases in the CD4 T cell count after initiation of combination antiretroviral therapy (cART). Patients in the HLA-Bw4
homozygote group had lower median increases in the CD4 T cell count than did those in the HLA-Bw6 homozygote group ( ) after cARTPp .01
initiation. The number of patients refers to the number of individuals with uninterrupted and successful cART for the respective follow-up times. The
changes in the CD4 T cell count from baseline were standardized to the median baseline CD4 T cell count of the combined cohort (i.e., 250 cells/
mL). Solid line, median increases in the CD4 T cell count of 849 HIV-infected individuals (All) from the Swiss HIV Cohort Study, irrespective of HLA-
Bw4 and HLA-Bw6 status; bars, SEs estimated from the mixed model.
our models allowed the slopes of the trend-line segments to
depend on baseline CD4 T cell counts in addition to other
covariate information (CCR5D32 carriage, age, and cART reg-
imen). For comparisons, estimated changes in the CD4 T cell
count from baseline were standardized to the median baseline
CD4 T cell count (i.e., 250 cells/mL).
Results. One hundred seventy-eight participants in SHCS
and 87 participants in WAHIV were included in the study. The
distribution of HLA-Bw4 homozygotes (Bw4/Bw4), heterozy-
gotes (Bw4/Bw6), and HLA-Bw6 homozygotes (Bw6/Bw6) was
similar among study participants (16%, 48%, and 36%, re-
spectively) and among 1551 healthy individuals from the West-
ern Australian Bone Marrow Registry (13%, 46%, and 40%,
respectively; , by the x2 test) and did not differ signifi-Pp .3
cantly between SHCS and WAHIV participants.
The HLA-Bw4 homozygote, HLA-Bw4/Bw6 heterozygote,
and HLA-Bw6 homozygote groups did not differ significantly
with regard to the median CD4 T cell count before cART ini-
tiation (248, 240, and 273 cells/mL, respectively; , byPp .5
analysis of variance). The median HIV RNA levels at baseline
were similar for the HLA-Bw4 homozygote, HLA-Bw4/Bw6 het-
erozygote, and HLA-Bw6 homozygote groups (4.8, 4.8, and 4.9
log10 copies/mL, respectively). Of the 265 participants, 195
(74%) had received uninterrupted, successful cART for 12
years, and 120 (45%) had received it for 14 years (figure 1).
The 3 groups did not differ with regard to the duration of
follow-up ( , by analysis of variance). A median of 12Pp .8
measurements of the CD4 T cell count (interquartile range, 8–
16) were analyzed per patient.
After 4 years of successful cART, the median increase in the
CD4 T cell count in the HLA-Bw4 homozygote group was 258
cells/mL, which was smaller than the increase in the HLA-Bw6
homozygote group (363 cells/mL; ) (table 1). The dif-Pp .01
ferences between the HLA-Bw4 and HLA-Bw6 homozygote
groups remained statistically significant after adjustment for
age, carriage of CCR5D32, and commencement of cART that
included a protease inhibitor ( ). When we excludedPp .02
individuals with the HLA alleles that are most consistently as-
sociated with protective effects (HLA-B*57 and HLA-B*27 [1,
8, 9]) or detrimental effects (HLA-B*35P(x) and HLA-B ho-
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Table 1. Median increases in the CD4 T cell count after 2 and 4 years of successful,
uninterrupted combination antiretroviral therapy.
Characteristic
No. of
patients
Median increase in the CD4
T cell count (IQRa) P
2 Years 4 Years Unadjusted Adjustedb
All patients 265 241 (133–361) 325 (194–473)
HLA allele group
Bw4/Bw4 42 197 (96–311) 258 (135–397) Reference Reference
Bw6/Bw4 127 240 (134–359) 321 (191–469) .10 .08
Bw6/Bw6 96 260 (151–381) 363 (227–515) .01 .02
CCR5D32
Not present 199 242 (135–362) 336 (202–487) Reference Reference
Presentc 51 236 (130–356) 290 (162–436) .34 .39
Age
40 years 119 222 (118–339) 299 (173–442) Reference Reference
!40 years 146 255 (147–376) 346 (214–495) .10 .06
Protease inhibitors
in regimen
No 115 240 (133–359) 336 (205–485) Reference Reference
Yes 150 241 (134–361) 316 (187–462) .86 .88
HLA-B*57
Not present 237 243 (136–364) 329 (197–479) Reference Reference
Present 28 220 (115–337) 296 (167–441) .06 .04
HLA-B*27
Not present 244 238 (131–358) 326 (193–477) Reference Reference
Present 21 267 (157–390) 333 (199–484) .77 .75
HLA-B*35P(x)d
Not present 247 242 (135–362) 325 (191–477) Reference Reference
Present 18 224 (119–343) 353 (215–508) .83 .90
HLA-B status
Heterozygous 249 238 (131–358) 325 (192–475) Reference Reference
Homozygous 16 291 (178–417) 353 (217–507) .61 .39
NOTE. The changes in the CD4 T cell count from baseline were standardized to the median baseline
CD4 T cell count of the combined cohort (i.e., 250 cells/mL). Increases in the CD4 T cell count that differ
significantly from the reference group are shown in boldface font. IQR, interquartile range.
a IQRs were estimated from the mixed model.
b P values adjusted for CCR5D32, age, and use of a protease inhibitor in the initial combination antiretroviral
therapy regimen.
c Results of CCR5 typing were not available for 15 individuals.
d HLA-B*3502, -B*3503, -B*3504, and -B*5301.
mozygosity [10]) on untreated HIV infection, the lower in-
creases in the CD4 T cell count for the HLA-Bw4 homozygote
group persisted (it was 100 cells/mL lower than that for the
HLA-Bw6 homozygote group; in unadjusted analyses).Pp .03
When female patients and nonwhite patients were included
( ), the median increase in the CD4 T cell count fornp 368
the HLA-Bw4 homozygote group after 4 years of successful
cART was 88 cells/mL smaller than that for the HLA-Bw6 ho-
mozygote group (unadjusted and adjusted P values were .04
and .06, respectively) and 86 cells/mL smaller than that for the
HLA-Bw4/Bw6 heterozygote group (unadjusted and adjusted P
values were both .04).
Carriage of the HLA-Bw4 80T variant was associated with
impaired recovery of the CD4 T cell count ( , comparedPp .04
with Bw6/Bw6), whereas this effect was less pronounced for
carriage of the HLA-Bw4 80I variant and was not statistically
significant. Because only 9 individuals had HLA-Bw4 homo-
zygosity without carriage of HLA-Bw4 80T, we could not assess
the relative importance of HLA-Bw4 homozygosity versus HLA-
Bw4 80T carriage. In comparison with all SHCS participants
(i.e., including 849 patients who did not have HLA typing
results but who had received uninterrupted, successful cART),
the median increases in the CD4 T cell count in our sample
( ) were lower for the HLA-Bw4 homozygote group andnp 265
higher for the heterozygote group and the HLA-Bw6 homo-
zygote group (figure 1).
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There was no significant difference between the SHCS and
WAHIV populations in terms of trends in the increase in the
CD4 T cell count ( ) or with regard to the HLA-Bw4Pp .7
effects ( ). The estimated rates of change for differentialPp .6
effects of HLA-Bw4 homozygosity, compared with HLA-Bw6
homozygosity, on recovery of the CD4 T cell count were similar
in the SHCS and WAHIV populations (0.045 vs. 0.042
square root CD4 T cell counts/month). Age was the only pa-
rameter with a significantly different effect ( ) on re-Pp .04
covery of the CD4 T cell count between the SHCS and WAHIV
cohorts.
The unexpected association of HLA-Bw4 homozygosity with
impaired recovery of the CD4 T cell count led us to assess
whether the impact of HLA-Bw4 homozygosity on CD4 T cell
dynamics before commencement of cART in our population
differed from that in previous reports [3]. In 95 SHCS partic-
ipants with known dates of HIV seroconversion, the hazard of
developing AIDS or reaching a CD4 T cell count !500 cells/
mL was significantly lower in the HLA-Bw4 homozygote group
(hazard ratio, 0.36; , by Cox regression), confirmingPp .005
the protective role of HLA-Bw4 homozygosity in untreated HIV
infection.
Discussion. HLA-Bw4 homozygosity was associated with
an impaired recovery of the CD4 T cell count after com-
mencement of cART. This contrasts with the protective effects
of HLA-Bw4 homozygosity during untreated HIV infection [3].
There was a trend towards poorer CD4 T cell recovery in pa-
tients in the HLA-Bw4/Bw6 heterozygote group. Additional
studies are warranted to determine the contribution of dom-
inant or recessive effects of HLA-Bw4/Bw6 on recovery of the
CD4 T cell count. Carriage of HLA-B*57, which has been con-
sistently associated with protective effects in untreated HIV
infection [11, 12], tended to correlate with an impaired recovery
of the CD4 T cell count during cART. This is in line with recent
observations that described a trend toward poorer post-cART
survival [13] and an impaired CD4 T cell recovery in the initial
years of cART [14] in individuals carrying HLA-B*5701.
The reasons for the differing effects of HLA-Bw4 and HLA-
Bw6 alleles before and after commencement of cART remain
unclear. The slower decrease in the CD4 T cell count and the
lower rate of AIDS-related events before commencement of
cART could lead to a delay in cART initiation, and a longer
duration of untreated HIV infection may cause a more pro-
found and unrecognized depletion of T cell subsets [15]. In
this case, the slower decrease in the CD4 T cell count in in-
dividuals with favorable genotypes before receipt of cART could
lead to a slower recovery of the CD4 T cell count after receipt
of cART. Because !20% of the study participants had known
dates of HIV seroconversion, we could not assess whether pa-
tients in the HLA-Bw4 homozygote group had been infected
for a longer period. Alternatively, the unfavorable effect of HLA-
Bw4 homozygosity could point toward immunogenetic mech-
anisms (e.g., interactions between natural killer cells and T cells)
that may play an important role in CD4 T cell homeostasis
during cART. It remains to be determined whether the genetic
association shown in this study can be explained by further
analysis of patients’ immunogenetic characteristics. Genetic
variation in HLA alleles has a profound influence on the ef-
fectiveness of cellular immune responses, on viral escape and
reversion, and on the impact of escape mutations on viral fitness
in untreated HIV infection [1]. However, given the dramatic
impact of cART on HIV replication, we anticipate that these
mechanisms are not major determinants of CD4 T cell recovery
and that they do not explain the influence of host genetic factors
observed in our study.
Protective genotypes in untreated HIV infection (CCR5D32
deletion and HLA-B*57) were associated with slightly lower
increases in the CD4 T cell count after commencement of cART.
Although these effects were not statistically significant, this ob-
servation is in line with the finding that some genotypes with
favorable effects before receipt of cART may be associated with
opposite effects after receipt of cART.
The lower increases in the CD4 T cell count persisted when
we excluded individuals who carried the HLA alleles most con-
sistently associated with protective or detrimental effects. Nev-
ertheless, we cannot exclude that effects of a small number of
constituent HLA alleles within the HLA-Bw4 and HLA-Bw6
groups and not broader differences between the HLA-Bw4 and
HLA-Bw6 motifs per se explain the different biological effects.
Because of the extreme polymorphism at the HLA-B locus and
the multitude of additional important genetic determinants in
HIV infection, the effects of single HLA alleles would only be
evident in very large cohorts. With the exception of the effect
of age, there were no significant differences between partici-
pants from the SHCS and WAHIV cohorts, suggesting that our
findings are representative for similar populations.
Our findings and previous studies from the SHCS [16] sug-
gest that a substantial minority of HIV-infected patients dem-
onstrate slow and/or incomplete recovery of the CD4 T cell
count that cannot be sufficiently predicted by the current pre-
treatment clinical assessment. Because of the favorable effects
of HLA-Bw4 homozygosity before commencement of cART, it
could be erroneously anticipated that HLA-Bw4 homozygotes
recover CD4 T cells particularly well.
This study adds to the growing knowledge about host genetic
factors that influence the efficacy and tolerability of cART [13,
17]. It is uncertain at this stage whether the impaired recovery
of the CD4 T cell count among patients with HLA-Bw4 ho-
mozygosity is associated with diminished recovery of functional
cellular immune responses or with higher morbidity after cART
initiation. Additional studies are warranted to clarify whether
individualizing therapy for HIV infection on the basis of the
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host’s genetic factors would optimize the timing and the efficacy
of cART.
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